<DOC>
	<DOCNO>NCT02622646</DOCNO>
	<brief_summary>Haemophilia A inherited bleeding disorder cause deficiency factor VIII ( FVIII ) . Patients severe hemophilia A FVIII plasma concentration less than1 IU/dL experience spontaneous trauma-induced bleeds . Joint bleeds lead hemophilic arthropathy result progressive disability . Patients moderate hemophilia ( FVIII level 1-5 IU/dL ) characterize few hemarthroses , usually trauma-induced , decreased likelihood develop arthropathy . This clinical observation lead use prophylactic FVIII infusion convert patient´s bleed phenotype severe moderate result decrease prevent arthropathy . Prophylactic regimen may effective base standard fixed-dose protocol ( assume one approach fit patient ) phenotypic dose determine bleed pattern , protect patient severe haemophilia joint damage cause spontaneous activity-triggered bleeding . Individualized treatment haemophilia A take consideration available information patient , phenotypic bleeding pattern . Some factor contribute observed interpatient variability include baseline residual FVIII activity , pharmacokinetic ( PK ) profile replacement factor , individual 's level physical activity perceive risk traumatic bleeding , presence absence joint disease , presence comorbidities adherence dose regimen . Objectives : Identify analyze cause ( ) poor bleed control patient prophylaxis treatment study clinical impact `` personalized pilot program '' 1 year follow act specific cause . 1 . Describe PK parameter patient prophylaxis treatment Advate® . 2 . Analyze difference PK parameter non-controlled v well control patient . 3 . Identify cause poor clinical outcome non-controlled patient . Patients ' individual variable influence bleed risk study ( individual PK , bleed pattern , joint status , physical activity , life style patient 's adherence ) . 4 . Study improvement clinical outcome ( ABR Joint status ) 1 year Personalized Prophylaxis Program act specifically previously identify cause bleed non-controlled patient ( name : short half-life , high bleeding pattern , joint damage , high risk physical activity , active life style poor patient 's adherence ) .</brief_summary>
	<brief_title>Personalized Prophylactic Treatment With Advate® Severe Moderate Haemophilia A Patients</brief_title>
	<detailed_description>Research Question : - Is standard prophylaxis effective hemophilia A patient ? - Which cause poor clinical response patient prophylactic treatment ? - Can difference PK impact clinical outcome effectiveness prophylaxis ? - For give group poor control patient standard prophylaxis , may personalize prophylaxis improve clinical outcome act specific cause ( ) ? Study Background &amp; Rationale : Haemophilia A inherited bleeding disorder cause deficiency factor VIII ( FVIII ) . Patients severe hemophilia A FVIII plasma concentration less than1 IU/dL experience spontaneous trauma-induced bleeds . Joint bleeds lead hemophilic arthropathy result progressive disability . Patients moderate hemophilia ( FVIII level 1-5 IU/dL ) characterize few hemarthroses , usually trauma-induced , decreased likelihood develop arthropathy . This clinical observation lead use prophylactic FVIII infusion convert patient´s bleed phenotype severe moderate result decrease prevent arthropathy . Prophylactic regimen may effective base standard fixed-dose protocol ( assume one approach fit patient ) phenotypic dose determine bleed pattern , protect patient severe haemophilia joint damage cause spontaneous activity-triggered bleeding . Individualized treatment haemophilia A take consideration available information patient , phenotypic bleeding pattern . Some factor contribute observed interpatient variability include baseline residual FVIII activity , pharmacokinetic ( PK ) profile replacement factor , individual 's level physical activity perceive risk traumatic bleeding , presence absence joint disease , genotype , presence comorbidities adherence dose regimen . The PK response FVIII vary patient important clinical implication treatment . Although PK affect patient characteristic , relationship weak infer result individual , require , PK must measure . An important determinant efficacy prophylaxis length time individual spends low level coagulation factor . According exist International Society Thrombosis Haemostasis ( ISTH ) guideline measurement PK clinical practice require adult patient total 8 sample ( 5 child ) take period 48 h. It require significant commitment time patient , family overnight hospital admission may require . The Bayesian estimation method use population PK model base FVIII level large population patient mathematical/ statistical framework estimate PK individual patient minimal data . Several study employ technique FVIII limit number patient . Using strategy , patient´s coagulation factor half-life may calculate two three time point , reduce inconvenience patient , discomfort venipuncture cost sample hand assay . This methodology facilitate measurement PK routine clinical practice . Knowledge individual 's PK response replacement factor help determine dose level well frequency administration need achieve optimal level deficient hemostatic factor . In particular , achieve ideal peak level help reduce risk bleeding related repetitive physical activity , whereas minimize time spend trough level 1 IU/dL help reduce breakthrough bleed event . The effect patient´s FVIII half-life potentially significant impact prophylactic regimen , whereas change frequency dose increase dose/kg FVIII small effect level . Different trough level may target , depend circumstance : high level may desire manage target joint , highly active patient , prone bleeding ; alternatively , low level may allow patient bleed long time . Last study demonstrate utility prophylaxis dose tailor individual PK similar result phenotypic dose few infusion , maybe , option could increase treatment adherence . Besides , PK monitoring could cost-effective dose compare standard dosage . Adherence prophylaxis regimens another patient-specific factor influence plasma level bleed risk . There two definition adherence haemophilia , adherence percentage infusion within specify dose range ( adherence dose ) percentage week without missed dos ( adherence frequency ) . Different study show bleeding rate higher nonadherent patient , old patient likely miss dos . Strategies improve adherence would expect decrease number bleeds , whereas poor adherence make PK dose tailor irrelevant . Use sparse blood sample Bayesian analysis measure pharmacokinetics , use information tailor dose prophylaxis previously report . Clinical implementation method available information patient ( bleed pattern , joint status , genetic mutation , adherence , etc . ) , lack . Exploratory study use PK tailor prophylaxis require establish safety efficacy approach . This procedure could allow individualization treatment routine determination individual pharmacokinetics clinic , potentially make prophylaxis cost-effective . Primary Endpoint : Identify analyze cause ( ) poor bleed control patient prophylaxis treatment study clinical impact `` personalized pilot program '' 1 year follow act specific cause . 1 . Describe PK parameter patient prophylaxis treatment Advate® 2 . Analyze difference PK parameter non-controlled v well control patient 3 . Identify cause poor clinical outcome non-controlled patient . Patients ' individual variable influence bleed risk study ( individual PK , bleed pattern , joint status , physical activity , life style patient 's adherence ) . 4 . Study improvement clinical outcome ( ABR Joint status ) 1 year Personalized Prophylaxis Program act specifically previously identify cause bleed non-controlled patient ( name : short half-life , high bleeding pattern , joint damage , high risk physical activity , active life style poor patient 's adherence ) . Duration subject participation : One year Total number subject enrol : 25-30 patient Specific detail Treatment/Intervention : This prospective , open-label , observational study perform Hospital Universitari Politecnic La Fe Valencia , Spain . This study include patient severe moderate haemophilia A prophylactic treatment rFVIII ( Advate® ) . 1 . The study start determination individual PK sparse blood sampling ( 2-3 blood sample ) Bayesian analysis ( use myPKFiT Medical Device ) . The PK parameter cohort patient prophylaxis Advate® describe . 2 . Patients divide two group accord clinical outcome ( Bleeding Episodes ) previous year : 1 . Well control patient : Patients adequate disease control routine clinical practice ( AJBR≤2 , non-severe ABR≤5 severe ABR≤2 ) ( Ministerio de Sanidad , Servicios Sociales e Igualdad . Gobierno de España ; 2012 ) 2 . Poor control patient : Patients poor disease control , base international guideline : AJBR &gt; 2 , ABR &gt; 2 severe BE ABR &gt; 5 non-severe BE 3 . Differences PK parameter 2 group analyze compare adjusting age weight : a. Half-life ( h ) b . Clearance ( dl/h ) c. Volume steady state ( L ) d. Time FVIII level 1 % ( h ) 4 . Non-controlled patient study interviewed identify cause poor disease control . Patients ' individual variable influence bleed risk study : 1 . Individual PK parameter ( See bullet point 3 ) 2 . Bleeding pattern : Haemophilia Severity Score 3 . Joint status ( Gilbert score HJHS ) 4 . Physical activity : Category Risk 1 , 2 3 5 . Patient 's adherence : Adherence index ( AI ) 5 . After identify patient individual cause ( ) poor bleed control , `` Pilot Program Personalized Prophylaxis '' design act specific factor may cause bleed despite prophylaxis . 1 . Shorter half-life compare Advate PK Population ( graph display myPKFiT ) • Prophylaxis adjust individual PK use recommendation myPKFiT Medical Device* . 2 . Patients bleed phenotype : HSS &gt; 0.79 ( severe HA ) HSS &gt; 0.47 ( moderate HA ) - Prophylaxis adjusted increase level accord bleed phenotype* 3 . Patients joint damage least one target joint ( least score 3 Gilbert scale /or least score 3 Pettersson scale and/or Chronic synovitis evidence ultrasound . ) • Prophylaxis adjust increase level accord Joint status* 4 . Physical activity : Category &gt; 1 - Prophylaxis adjust : 1 . Match day physical activity day infusion 2 . Increase level accord physical activity* e. Patient 's poor adherence : • Monthly session together psychologist pharmacist HTC schedule address adherence issue . myPKFiT displayed graph use explain availability elimination FVIII blood . *All dose adjustment make base clinical data , also base knowledge experience responsible physician patient . 6 . Using prospective design , patient study 12 month follow start `` Personalized Prophylaxis Program '' . Patient´s clinical state assess least 2 time per year ( normally 2-4 visit per year depend disease severity ) . 1 . AJBR ABR ( severe , non-severe , spontaneous traumatic bleeding episode ) collect month 6 12 . 2 . Joint status , Gilbert HJS measure month 12 . 3 . Adherence index ( AI ) calculate month 12 4 . Quality Life measure month 12 . - This study conduct without significant change medical treatment patient . - The study currently approval process local Clinical Research Ethics Committee conduct accordance declaration Helsinki amendment . An informed consent obtain patient include study . Statistical Methods : Statistical analysis perform R software ( version 3.2.2 ) . Data describe mean , standard deviation , median interquartile range quantitative variable relative absolute frequency categorical variable . P-values &lt; 0.05 consider statistically significant . For analysis , Institution 's Biostatistical Unit support study . A non-parametric statistical method ( Wilcoxon test ) use simple comparison PK parameter group patient ( clinically control uncontrolled prophylaxis treatment ) . The effect time 1 IU/dL , Vss , Cl half-life annual bleeding rate ( ABR AJBR ) analyze multivariate analysis group . Multivariate analysis annual bleeding rate ( dependent variable ) perform separately potential factor associate bleed rate PK parameter , physical activity , adherence treatment schedule quality life . In instance regression model utilize negative binomial distribution use . Annualized FVIII consumption rate treatment relate AEs prophylaxis group compare use Mann-Whitney U-test . The sample size 25-30 patient calculate provide 90 % power detect mean treatment difference four ABR AJBR episodes two-sided = 0.05 , assume standard deviation ( SD ) 6 ABR AJBR episodes six month . The sample size assume ABR variance least observed compliant subject previous study . Sample size calculate use NQUERY , version 5.0 , module MOT 1-1 ( Statistical Solutions , Saugus , MA , USA ) .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Adults adolescent older 12 year Patients Prophylactic treatment Advate® least 1 year Written inform consent . History FVIII inhibitor ( titre ≥ 0.6 BU [ Bethesda unit ] ) detectable FVIII inhibitor screen ( titre ≥ 0.4 BU ) , Another haemostatic defect Need major surgery . Withdrawal inform consent</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>